Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma

Clinical Biochemistry

Volumn 41, Issue 14-15, 2008, Pages 1131-1139

  Atta, Mohamed M ^a   El Masry, Samir A ^b   Abdel Hameed, Mohamed ^a   Baiomy, Hosam A ^a   Ramadan, Naglaa E ^a  

^a BENHA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Anti p53 antibodies; ELISA; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ALPHA-FETOPROTEINS; ANTIBODIES, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DEMOGRAPHY; EGYPT; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55849144368     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.06.006     Document Type: Article

References (28)

1. Liovet J.M., Fuster J., and Bruix J. The Barcelona approach: diagnosis, staging and treatment of hepatocellular carcinoma. Liv Transplant 10 (2004) 115-120
2. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma of 7 staging system in an American cohort. Hepatology 41 (2005) 707-716
3. Lopez J.B. Recent development in the first detection of hepatocellular carcinoma. Clin Biochem 26 (2005) 65-79
4. El-Zayadi A.R., Badran H.M., Barakat E.M., et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 11 (2005) 5193-5198
5. Michielsen P.P., Francque S.M., and Dongan J.L. Viral hepatitis and hepatocellular carcinoma. World J Sur Oncol. 3 (2005) 27
6. Grieco A., Pompili M., Caminiti G., et al. Prognostic factors for survival in patients with early intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP and BCLC staging systems in a single Italian centre. Gut 54 (2005) 411-418
7. Abdel-Gafar Y., Sleem H., Tawfik M., et al. Percutaneous ethanol injection in large size and multiple HCC: two years follow-up in 165 patients. Med J Cairo Univ 70 (2002) suppl II December
8. Vauthy B.J., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 20 (2002) 1527-1536
9. Okochi O., Hibi K., Uemura T., et al. Detection of mitochondrial DNA alterations in the serum of heptocellular carcinoma patients. Clin Can Res 8 (2002) 2875-2878
10. Kew M.C. Hepatic tumors and cysts. In: Feldman M., Friedman L.S., and Sleisenger M.H. (Eds). Gastrointestinal and liver disease: pathophysiology, diagnosis, management. 7th ed (2002), Saunders, Philadelphia, London, New York, St. Louis, Sydney 1577-2802
11. Guan Y.S., He Q., and La Z. Roles of p53 in carcinogenesis, diagnosis and treatment of hepatocellular carcinoma. J Can Molec 2 (2006) 191-197
12. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329 (1993) 1318-1327 Comment in: N Engl J Med 1994; 330: 864-5
13. Shiota G., Kishimoto Y., and Suyama A. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol 27 (1997) 661-668
14. Charuruks N., Tangkuvanich P., and Voravud V. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol 36 (2001) 830-836
15. Okuda K., Ohtsuki T., Obta H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer 56 (1985) 918-928
16. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28 (1998) 751-755
17. Tateishi R., Yoshida H., Shiina S., et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54 (2005) 419-425
18. Engvall E., and Perlmann P. Enzyme Linked Immunosorbent Assay (ELISA): quantitative assay of IgG. Immunochemistry 8 (1971) 871-878
19. Saffroy R., Lelong J.C., Azoulay D., et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 79 (1999) 604-610
20. Akere A., and Otegbayo J.A. Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma. Singapore Med J 48 (2007) 41-44
21. Soini Y., Chia S.C., Bennett W.P., et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinoma from Mexico. Carcinogenesis 17 (1996) 1007-1012
22. Sitruk V., Vaysse J., Chevret S., et al. Prevalence and prognostic value of serum anti-p53 in hepatocellular carcinoma. A study of 159 patients. Gastroenterol Clin Biol 24 (2000) 1159-1163
23. Tangkijvanich P., Janchai A., Charuruks N., et al. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma. Asian Pac J Allergy Immunol 18 (2000) 237-243
24. De Benedetti V.M., Welsh J.A., Trivers G.E., et al. p53 is not mutated in hepatocellular carcinomas from Alaska natives. Can Epidem Biomarkers Prev 4 (1995) 79-82
25. Ryder S.D., Rizzi P.M., Volkmann M., et al. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 49 (1996) 295-299
26. Parasole R., Izzo F Perrone F., et al. Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Can Res 7 (2001) 3504-3509
27. Dong-Dong L.D., and Xi-Ran Z.X. Plasma 249 ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area. J Cell Mol Med 7 (2003) 89-92
28. Lee K.C., Crowe A.J., and Barton M.C. P53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol and Cell Biol 19 (1999) 1279-1288